The US Patent and Trademark office has issued a new patent for 'Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation' on behalf of pharmaceutical firm BioChemics.

            New technology developed under the patent will allow BioChemics scientists to devise and sell new treatments designed to help awkward and inflamed wounds that would otherwise take a very long time to heal.
Target medical conditions include ulcers, cancer, myopathy, diabetic neuropathy and physical injury suffered by the patient.

            Various topical formulations are covered by the patent, particularly those comprising a combination of retinoid Vitamin A and the blood vessel dilator methyl nicotinate in a stable emulsion.

            John Masiz, president of BioChemics Inc, said: "The type of wound we are dealing with here are generally ulcerative and are very difficult to treat with current treatment options; things like bed sores, diabetic foot ulcerations, traumatic injury etc."

            The market could prove lucrative as wound care was worth $14.9 billion in 2010, research firm Kalorama Information claims.